ATE463576T1 - Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten - Google Patents

Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten

Info

Publication number
ATE463576T1
ATE463576T1 AT01923265T AT01923265T ATE463576T1 AT E463576 T1 ATE463576 T1 AT E463576T1 AT 01923265 T AT01923265 T AT 01923265T AT 01923265 T AT01923265 T AT 01923265T AT E463576 T1 ATE463576 T1 AT E463576T1
Authority
AT
Austria
Prior art keywords
aggregate
production
uric acid
acid oxidase
polymer conjugates
Prior art date
Application number
AT01923265T
Other languages
English (en)
Inventor
Merry Sherman
Mark Saifer
L Williams
Michael Hershfield
Susan Kelly
Original Assignee
Mountain View Pharmaceuticals
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mountain View Pharmaceuticals, Univ Duke filed Critical Mountain View Pharmaceuticals
Application granted granted Critical
Publication of ATE463576T1 publication Critical patent/ATE463576T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT01923265T 2000-02-10 2001-02-07 Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten ATE463576T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/501,730 US6783965B1 (en) 2000-02-10 2000-02-10 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PCT/US2001/040069 WO2001059078A2 (en) 2000-02-10 2001-02-07 Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates

Publications (1)

Publication Number Publication Date
ATE463576T1 true ATE463576T1 (de) 2010-04-15

Family

ID=23994789

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01923265T ATE463576T1 (de) 2000-02-10 2001-02-07 Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten

Country Status (27)

Country Link
US (3) US6783965B1 (de)
EP (3) EP1254237B1 (de)
JP (2) JP5165826B2 (de)
KR (3) KR20070092329A (de)
CN (2) CN101735991B (de)
AT (1) ATE463576T1 (de)
AU (3) AU4997501A (de)
BE (1) BE2013C045I2 (de)
BR (1) BRPI0108386B8 (de)
CA (1) CA2398679C (de)
CY (3) CY1110142T1 (de)
CZ (1) CZ304864B6 (de)
DE (1) DE60141742D1 (de)
DK (3) DK1254237T3 (de)
ES (2) ES2343105T3 (de)
FR (1) FR13C0036I2 (de)
HU (1) HU227127B1 (de)
IL (3) IL151065A0 (de)
LU (1) LU92237I2 (de)
MX (1) MXPA02007545A (de)
NZ (1) NZ520434A (de)
PL (1) PL208064B1 (de)
PT (2) PT2305819E (de)
RU (3) RU2281954C2 (de)
TW (2) TW200914617A (de)
WO (1) WO2001059078A2 (de)
ZA (1) ZA200207206B (de)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
US7056713B1 (en) 1998-08-06 2006-06-06 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
PL202799B1 (pl) * 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US20060188971A1 (en) * 1998-08-06 2006-08-24 Duke University Urate oxidase
ATE414711T1 (de) 2001-06-28 2008-12-15 Mountain View Pharmaceuticals Polymerstabilisierte proteinasen
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
PT2298278E (pt) 2002-06-07 2016-02-25 Dyax Corp Prevenção e redução da perda de sangue e resposta inflamatória
US8129330B2 (en) * 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040062748A1 (en) 2002-09-30 2004-04-01 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
GEP20084486B (en) * 2002-12-26 2008-09-25 Mountain View Pharmaceuticals Polymer conjugates of interferon-beta with enhanced biological potency
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ（エチレングリコール）修飾化合物およびその用途
CN1849141A (zh) * 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
PL1625156T3 (pl) * 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
CA3050564A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
EP1814910A4 (de) * 2004-11-11 2009-04-29 Affymax Inc Neue am erythropoietinrezeptor bindende peptide
WO2006062685A2 (en) * 2004-11-11 2006-06-15 Affymax, Inc. Novel peptides that bind to the erythropoietin receptor
EP1868652A2 (de) * 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen
KR20080009111A (ko) 2005-04-11 2008-01-24 새비언트 파마수티컬즈 인크. 유레이트 옥시다아제의 변이형 및 이의 용도
US20080159976A1 (en) * 2005-04-11 2008-07-03 Jacob Hartman Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
TWI418564B (zh) * 2005-04-11 2013-12-11 沙凡特藥品公司 利用陽離子界面活性劑之蛋白質純化
MX2007012548A (es) 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US8148123B2 (en) * 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
EP1883425A1 (de) * 2005-05-23 2008-02-06 Universite De Geneve Injizierbare superparamagnetische nanoteilchen zur behandlung von hyperthermie und verwendung zur bildung eines hyperthermischen implantats
US7550433B2 (en) * 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US8324159B2 (en) * 2005-06-03 2012-12-04 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
US7919461B2 (en) 2005-06-03 2011-04-05 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
KR101288027B1 (ko) * 2006-04-12 2013-07-22 새비언트 파마수티컬즈 인크. 양이온 계면활성제를 이용한 단백질 정제 방법
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
JP2012531596A (ja) 2009-06-25 2012-12-10 サヴィエント・ファーマシューティカルズ・インコーポレイテッド Ｐｅｇ化ウリカーゼ療法における血清尿酸をモニタリングすることにより注入反応の危険性および抗体媒介性効果消失を予測するための方法およびキット
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
WO2011127393A2 (en) 2010-04-08 2011-10-13 Georgia Tech Research Corporation Variants of ancestral uricases and uses thereof
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
CA2913476A1 (en) 2013-06-07 2014-12-11 Allena Pharmaceuticals, Inc. Compositions, methods, and devices for dialysis
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
IL247942B (en) 2014-03-27 2022-09-01 Dyax Corp Compositions and methods for drops in macular edema as a result of diabetes
WO2016187026A1 (en) 2015-05-15 2016-11-24 Medimmune, Llc Improved uricase sequences and methods of treatment
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
US11286307B2 (en) 2015-12-11 2022-03-29 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN116637177A (zh) 2016-11-11 2023-08-25 好利恩治疗美国公司 泼尼松和尿酸酶分子的组合疗法及其用途
CN111373034A (zh) 2017-07-07 2020-07-03 艾乐娜制药有限公司 重组尿酸酶
US20190309269A1 (en) 2018-03-20 2019-10-10 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating hyperuricemia and gout
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
CN109055260B (zh) * 2018-08-08 2021-11-09 淮海工学院 弯曲芽孢杆菌alkaAU及产尿酸氧化酶方法、产品与应用
US12121566B2 (en) 2019-01-30 2024-10-22 Horizon Therapeutics Usa, Inc. Methods for treating gout
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
JP7404510B2 (ja) * 2019-05-10 2023-12-25 重慶派金生物科技有限公司 ポリエチレングリコール修飾尿酸オキシダーゼ
AU2021209045A1 (en) 2020-01-13 2022-07-28 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating pediatric hereditary angioedema attack
AU2021324665A1 (en) 2020-08-10 2023-04-13 Horizon Therapeutics Usa, Inc. Methods of treating gout
CN114181917B (zh) * 2022-02-14 2022-06-03 潍坊华卓生物科技有限公司 一种改造尿酸酶、基因序列、制备方法及应用
CN117051026A (zh) * 2022-05-06 2023-11-14 江苏恰瑞生物科技有限公司 一种特异性尿酸结合物固定化树脂及其制备方法和应用
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279486C (de)
FR6301M (de) * 1967-03-29 1968-09-09
US3616231A (en) 1968-11-14 1971-10-26 Boehringer Mannheim Gmbh Process for the production of uricase
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5599189A (en) 1979-01-22 1980-07-28 Mihama Hisaharu Modified uricase free from antigenicity and its preparation
JPS55135590A (en) 1979-04-05 1980-10-22 Mihama Hisaharu Modified asparaginase and uricase and their preparation
CH651308A5 (de) 1980-07-01 1985-09-13 Hoffmann La Roche Interferone und deren herstellung.
JPS57192435A (en) 1981-05-20 1982-11-26 Toyobo Co Ltd Modified polypeptide
DE3126759A1 (de) 1981-07-07 1983-01-27 Boehringer Mannheim Gmbh, 6800 Mannheim Loesliche leber-uricase, verfahren zu ihrer herstellung und verwendung
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
EP0229108B1 (de) * 1985-06-26 1990-12-27 Cetus Corporation Solubilisierung von proteinen für pharmazeutische zusammensetzungen mittels polymerkonjugierung
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DD279486A1 (de) 1986-03-10 1990-06-06 Akad Wissenschaften Ddr Verfahren zur aktivierung von hydroxylgruppenhaltigen polymeren verbindungen
JPS6255079A (ja) * 1986-04-23 1987-03-10 Mihama Hisaharu 修飾ウリカ−ゼ
JPH085506B2 (ja) * 1986-08-25 1996-01-24 日東製器株式会社 缶容器
DD279489A1 (de) 1986-12-11 1990-06-06 Leuna Werke Veb Verfahren zur herstellung optisch transparenter epoxidharzformmassen
US5080891A (en) * 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4847325A (en) 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5955336A (en) * 1988-08-17 1999-09-21 Toyo Boseki Kabushiki Kaisha DNA sequence for uricase and manufacturing process of uricase
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
KR0159107B1 (ko) 1989-07-13 1998-11-16 쟝 르쌍드뢰 우레이트 산화효소 활성 단백질, 이 단백질을 암호화하는 재조합 유전자, 발현 벡터, 미생물 및 형질전환세포
NZ234453A (en) * 1989-07-13 1993-01-27 Sanofi Sa Recombinant dna encoding urate oxidase, and vector, host, protein and pharmaceutical compositions associated therewith
US5286637A (en) 1989-08-07 1994-02-15 Debiopharm, S.A. Biologically active drug polymer derivatives and method for preparing same
JPH03148298A (ja) 1989-11-01 1991-06-25 Sumitomo Pharmaceut Co Ltd 修飾ペプチドおよびその製造方法
SU1730145A1 (ru) * 1990-05-04 1992-04-30 Всесоюзный научно-исследовательский институт текстильно-галантерейной промышленности Способ стабилизации уриказы
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5653974A (en) 1990-10-18 1997-08-05 Board Of Regents,The University Of Texas System Preparation and characterization of liposomal formulations of tumor necrosis factor
AU1674292A (en) * 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
WO1994019007A1 (en) 1993-02-16 1994-09-01 Enzon, Inc. Ribosome inactivating protein compositions having reduced antigenicity
AU6586394A (en) * 1993-04-22 1994-11-08 Celtrix Pharmaceuticals, Inc. Conjugates of growth factor and bone resorption inhibitor
AU7113594A (en) 1993-06-21 1995-01-17 Enzon, Inc. Site specific synthesis of conjugated peptides
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
HUT75533A (en) * 1993-11-10 1997-05-28 Schering Corp Improved interferon polymer conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
JPH10510516A (ja) * 1994-12-07 1998-10-13 ノボ ノルディスク アクティーゼルスカブ アレルゲン性を減らしたポリペプチド
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
TW426523B (en) * 1995-04-06 2001-03-21 Hoffmann La Roche Interferon solution
FR2733914B1 (fr) * 1995-05-11 1997-08-01 Sanofi Sa Composition de liquide stable contenant de l'urate oxydase et composition lyophilisee pour sa preparation
US5853974A (en) 1995-06-07 1998-12-29 Chiron Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates
JPH09154581A (ja) 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
DK1007082T3 (da) 1997-01-15 2007-02-19 Phoenix Pharmacologics Inc Modificeret tumor nekrose faktor
ES2228052T3 (es) * 1998-06-01 2005-04-01 Genentech, Inc. Separacion demonomeros de anticuerpos de sus multimeros utilizando cromatografia de intercambio de iones.
US6783965B1 (en) * 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
US7056713B1 (en) 1998-08-06 2006-06-06 Duke University Urate oxidase
ATE298251T1 (de) 1998-08-06 2005-07-15 Mountain View Pharmaceuticals Peg-uricase konjugate und verwendung davon
PL202799B1 (pl) 1998-08-06 2009-07-31 Mountain View Pharmaceuticals Sposób izolowania urykazy w postaci tetramerycznej oraz wyizolowana tetrameryczna urykaza
US6425448B1 (en) 2001-01-30 2002-07-30 Cdx Gas, L.L.P. Method and system for accessing subterranean zones from a limited surface area
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
TWI538373B (zh) 2013-05-24 2016-06-11 中心微電子德累斯頓股份公司 切換式功率轉換器以及用於控制切換式功率轉換器的方法

Also Published As

Publication number Publication date
CN101735991B (zh) 2013-09-11
LU92237I2 (fr) 2013-09-03
KR20080098686A (ko) 2008-11-11
IL193365A (en) 2011-08-31
RU2557318C9 (ru) 2015-09-10
AU4997501A (en) 2001-08-20
WO2001059078A2 (en) 2001-08-16
CN1423699A (zh) 2003-06-11
HK1155203A1 (en) 2012-05-11
US7927852B2 (en) 2011-04-19
AU2009212900A1 (en) 2009-10-01
KR100884724B1 (ko) 2009-02-19
EP2196538B1 (de) 2014-10-01
JP2003521937A (ja) 2003-07-22
KR20070092329A (ko) 2007-09-12
BR0108386C1 (pt) 2011-12-20
MXPA02007545A (es) 2002-12-13
PT1254237E (pt) 2010-06-07
JP5165826B2 (ja) 2013-03-21
HUP0204544A2 (en) 2003-05-28
IL193365A0 (en) 2009-02-11
HK1144701A1 (en) 2011-03-04
EP2305819A1 (de) 2011-04-06
KR101054247B1 (ko) 2011-08-08
CN100491532C (zh) 2009-05-27
BRPI0108386B8 (pt) 2021-05-25
CA2398679A1 (en) 2001-08-16
US20080057048A1 (en) 2008-03-06
CZ20022982A3 (cs) 2003-01-15
HUP0204544A3 (en) 2007-05-02
BR0108386B1 (pt) 2017-10-31
ES2343105T8 (es) 2013-07-15
PL358539A1 (en) 2004-08-09
HK1056742A1 (zh) 2004-02-27
AU2001249975B2 (en) 2006-06-08
HU227127B1 (en) 2010-07-28
JP5341945B2 (ja) 2013-11-13
JP2011188861A (ja) 2011-09-29
US6783965B1 (en) 2004-08-31
CY2013028I2 (el) 2015-11-04
CZ304864B6 (cs) 2014-12-17
ES2524153T3 (es) 2014-12-04
PT2305819E (pt) 2015-06-01
ES2343105T3 (es) 2010-07-23
TW200914617A (en) 2009-04-01
CY1110142T1 (el) 2015-01-14
EP1254237B1 (de) 2010-04-07
DK2196538T3 (en) 2015-01-05
CY2013028I1 (el) 2015-11-04
DK1254237T3 (da) 2010-07-19
RU2352354C2 (ru) 2009-04-20
PL208064B1 (pl) 2011-03-31
IL151065A (en) 2008-12-29
IL151065A0 (en) 2003-04-10
US8921064B2 (en) 2014-12-30
ZA200207206B (en) 2003-05-06
DK2305819T3 (en) 2015-01-05
EP2305819B1 (de) 2014-11-12
RU2006107110A (ru) 2007-09-20
HK1143989A1 (en) 2011-01-21
CN101735991A (zh) 2010-06-16
FR13C0036I2 (fr) 2014-05-16
FR13C0036I1 (fr) 2013-08-09
BR0108386A (pt) 2002-10-29
CY1117264T1 (el) 2017-04-26
TWI322184B (en) 2010-03-21
DE60141742D1 (de) 2010-05-20
RU2281954C2 (ru) 2006-08-20
RU2009104003A (ru) 2010-08-20
CA2398679C (en) 2015-11-17
BE2013C045I2 (de) 2020-06-24
KR20020087934A (ko) 2002-11-23
RU2557318C2 (ru) 2015-07-20
EP2196538A1 (de) 2010-06-16
WO2001059078A3 (en) 2002-03-07
US20110287466A1 (en) 2011-11-24
AU2009212900B2 (en) 2011-12-08
EP1254237A2 (de) 2002-11-06
NZ520434A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
DE60141742D1 (de) Aggregat-freie harnsäureoxidase zur herstellung von nicht-immunogenen polymer-konjugaten
EP1196444B8 (de) Exendin-4 konjugate und ihre medizinische verwendung
PT1075281E (pt) Conjugados poliol-ifn-beta
DK1037657T3 (da) Alfainterferon-polymerkonjugat med foröget biologisk aktivitet og fremgangsmåder til fremstilling heraf
KR940019312A (ko) 폴리에틸렌 옥사이드로 개질된 단백질 및 폴리펩티드와 사이클로덱스트린의 동결 건조된 복합체
DE59904569D1 (de) Therapeutikum zur unterdrückung von schnarchgeräuschen
KR20210018526A (ko) 천연(텔로펩티드) 태반 콜라겐 조성물
DE60006100D1 (de) Lang wirkende insulinotrope peptide
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
KR880700668A (ko) 특정 생체조직 부위로의 전달을 위한 아미노산 킬레이트의 조성물
WO1998046257A8 (en) Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
NZ509633A (en) A recombinant chimeric PEG-uricase with a long circulatory life and reduced immunogenicity
DK0754229T3 (da) Afamin: et humant serum albumin-lignende protein
DK0450628T3 (da) Saccharidmidificerede, vandopløselæige proteiner
CA2341276A1 (en) Human anti-factor ix/ixa antibodies
AU6978887A (en) Method and compositions for increasing mammary parenchyma
Yuecel et al. Increased susceptibility to oxidative stress in lens tissues of sulfur dioxide exposed rats
ATE283284T1 (de) Verfahren zur herstellung von wespengift- allergenen mit verminderter ige-reaktivität
DE60223232D1 (de) Mucinpeptid mit immunstärkenden eigenschaften
NN Effect of some physiological changes on the binding of tenoxicam to human serum albumin
TH52654A (th) แอนตี-แอนจิโอจินิก เปปไทด์ ที่มีอายุยาวนาน
UA25289A (uk) Спосіб приготуваhhя горілки "імператорська"

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254237

Country of ref document: EP